Two-Year Backlog in Biologicals Manufacturing Hinders Medical R&D, Development of New Therapies for COVID-19
One area where COVID-19 has had a substantial impact is the development and manufacturing of medicines, medical devices, and pharmaceutical products. The CDMO industry is showing enormous growth and is projected to become a $315 billion industry by 2026. However, the demand for products skyrocketed so quickly that supply has not been able to keep pace. According to Dr. Ian White, president and CSO of Neobiosis, a UF Innovate | Sid Martin Biotech resident company that focuses on the science of regenerative medicine, demand has caused a two-year backlog of desperately needed cellular and acellular products for use in research and clinical trials directed at treating the COVID-19 virus and its complications (AKA Post-COVID Syndrome).
UF Innovate | Incubation Services Resident Signum Biosciences Launches Epicutis, a Professional Luxury Medical-Grade Skincare Line
UF Innovate | Sid Martin Biotech resident Signum Biosciences, a biopharma company with 20 years of topical drug development and skincare ingredient expertise, announced the launch of Epicutis, a new professional, medical-grade luxury skincare line.
Greater Gift, AGTC, and 2020 On-Site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials, announced a partnership with UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a biotechnology company developing genetic therapies for the treatment of rare inherited retinal diseases (IRDs), and mobile vision provider 2020 On-site, a company involved in IRD clinical research and provides complimentary eye exams and facilitates the delivery of eyeglasses to students in need.
AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, announced it will be a sponsor of the Achroma Corp program, No Roadblocks.
Tampa’s Morphogenesis Wants To Cure Cancer With an Affordable Shot
A group of scientists in Tampa is working to make treating cancer as easy as getting a shot. While most of today's cancer treatments tend to be toxic and expensive, UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, is working to develop immunotherapies that are safe and affordable.
UF Innovate Welcomes Lauren Asmus as Client Experience Manager
UF Innovate | Incubation Services is delighted to welcome Lauren Asmus as the program’s first Client Experience Manager. Lauren joined the team on August 16 and will serve clients and implement entrepreneurial programs at UF Innovate | Incubation Services’ facilities Sid Martin Biotech and The Hub.
DiaCarta Receives CE/IVD for its New COVID 19 test that Identifies Delta Plus and New Variants
UF Innovate | Sid Martin Biotech alum DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy, announced that its new QuantiVirus™ SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
Axogen’s Aim: Growing Tampa Into a Hub for Nerve Repair Treatment Technology
As a biotech company at the forefront of nerve repair treatment, UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, has always been near the front of the scientific curve.
Axogen, Inc. Appoints John H. Johnson to Board of Directors
UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that John H. Johnson has been appointed to its Board of Directors.
DiaCarta Q&A: Liquid Biopsy for Early Cancer Detection
DiaCarta is initiating a large-scale clinical development program, which will monitor cfDNA levels to determine early treatment outcomes of systemic therapy in all types of stage IV cancer.
